Exact Sciences Corp (EXAS) 25.56 $EXAS
Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 14, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is currently the second-leading cause of death in the United States, and if the World Health Organization is correct, it may wind up eclipsing heart disease for the dubious top spot sometime in the near...
AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
VolitionRx: The Future Of Cancer Screening
Ian Cassel - Seeking Alpha - Thu Feb 12, 8:18AM CST
Last September, I wrote an article on VolitionRx's (NYSEMKT: VNRX ) potential to revolutionize cancer screening. Since then, the company has continued to show promising data not only with colorectal cancer, but also pilot results with lung,...
VNRX: 4.15 (+0.15), EXAS: 25.56 (-0.54)
Swiss diagnostics firm acquires CRC molecular blood test
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:57AM CST
EXAS: 25.56 (-0.54)
Exact Sciences names Michael S. Wygza to board
M2 - Thu Feb 12, 6:36AM CST
Molecular diagnostics company Exact Sciences (NasdaqCM:EXAS) stated on Wednesday that it has elected Michael S. Wygza to its board of directors and to its Audit Committee.
RDUS: 50.37 (+0.63), EXAS: 25.56 (-0.54)
Exact Sciences Names Michael S. Wygza to its Board of Directors
Business Wire - Wed Feb 11, 9:32AM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced the appointment of Michael S. Wygza to its board of directors. Wygza most recently served as President, Chief Executive Officer and a member of the board of directors of Radius Health, Inc.
RDUS: 50.37 (+0.63), EXAS: 25.56 (-0.54)
'Fast Money' Recap: How to Trade in a Gyrating Stock Market
at The Street - Sat Feb 07, 4:00AM CST
The trading panel discussed the strong dollar, oil prices and Tesla's earnings next week.
TSLA: 203.77 (+0.89), EEM: 40.67 (+0.46), EOG: 96.92 (+2.12), EXAS: 25.56 (-0.54), TWTR: 48.50 (+0.55), GDX: 21.26 (+0.11), TLT: 128.19 (-1.33), SCHW: 29.13 (-0.83)
Check-Cap on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 11:29AM CST
EXAS: 25.56 (-0.54)
Exact Sciences and Mayo Clinic Extend, Expand Collaboration to Continue Fighting Cancer through Advanced Screening
Business Wire - Fri Feb 06, 6:00AM CST
Exact Sciences Corp. (NASDAQ: EXAS) and Mayo Clinic today announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.
EXAS: 25.56 (-0.54)
Exact Sciences to Participate in Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will take part in the Leerink Global Healthcare Conference in New York.
EXAS: 25.56 (-0.54)
Exact Sciences Announces Norton Healthcare to Adopt Cologuard
Business Wire - Wed Jan 28, 2:30PM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard(R), the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure.
EXAS: 25.56 (-0.54)
Exact Sciences' Puzzling Early Launch Trajectory Update For Cologuard - An Analysis
SNJBiostoxx - at Seeking Alpha - Wed Jan 21, 5:30AM CST
EXAS: 25.56 (-0.54)
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 18, 8:12AM CST
Source: Flickr user Eric Norris Cancer of any type is a terrifying disease to fight. There are simply so many unknowns associated with cancer, such as why it occurs in one person and not the next and what triggers its growth in the first place. ...
MRK: 58.81 (-0.07), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
The Liquid Biopsy Will Boost Revenue For Sequenom And Illumina
Doug Van Cuyk - at Seeking Alpha - Thu Jan 15, 10:36AM CST
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81), EXAS: 25.56 (-0.54)
Why You Shouldn't Bet Against Exact Sciences (EXAS) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:40AM CST
Exact Sciences is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors
EXAS: 25.56 (-0.54)
Exact Sciences reports Cologuard volume for 2014
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:58AM CST
EXAS: 25.56 (-0.54)
Why Shares of Foundation Medicine, Inc. Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 10:52AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of Foundation Medicine rose by more than...
FMI: 48.88 (+0.17), AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
Exact Sciences Offers Update on Cologuard's(R) Early Launch Trajectory
Business Wire - Mon Jan 12, 8:04AM CST
Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, more than 4,000 physicians wrote at least one prescription for the test and that as of December 31, the patient compliance rate was 74.6 percent. The Company estimates revenue during the fourth quarter of 2014 from Cologuard was approximately $1.5 million. Exact Sciences has not completed preparation of its financial statements for 2014 and this revenue estimate is based on preliminary data.
EXAS: 25.56 (-0.54)
In Case You Missed it, This New Cancer Study is Terrifying
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is possibly the scariest diagnosis a patient can be given. Within the United States cancer is the second-leading cause of death behind only heart disease. It was responsible for nearly 577,000 deaths in...
MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), EXAS: 25.56 (-0.54)
Exact Sciences Rises 1.99% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Jan 09, 4:44PM CST
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $28.27 to a high of $29.20. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $28.70 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 25.56 (-0.54)
Exact Sciences Shares Up 14.6% Since SmarTrend's Buy Recommendation (EXAS)
Comtex SmarTrend(R) - Fri Jan 09, 9:35AM CST
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on October 10th, 2014 at $25.17. In approximately 3 months, Exact Sciences has returned 14.62% as of today's recent price of $28.85.
EXAS: 25.56 (-0.54)
Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 14, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is currently the second-leading cause of death in the United States, and if the World Health Organization is correct, it may wind up eclipsing heart disease for the dubious top spot sometime in the near...
AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
VolitionRx: The Future Of Cancer Screening
Ian Cassel - Seeking Alpha - Thu Feb 12, 8:18AM CST
Last September, I wrote an article on VolitionRx's (NYSEMKT: VNRX ) potential to revolutionize cancer screening. Since then, the company has continued to show promising data not only with colorectal cancer, but also pilot results with lung,...
VNRX: 4.15 (+0.15), EXAS: 25.56 (-0.54)
Swiss diagnostics firm acquires CRC molecular blood test
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:57AM CST
EXAS: 25.56 (-0.54)
Exact Sciences names Michael S. Wygza to board
M2 - Thu Feb 12, 6:36AM CST
Molecular diagnostics company Exact Sciences (NasdaqCM:EXAS) stated on Wednesday that it has elected Michael S. Wygza to its board of directors and to its Audit Committee.
RDUS: 50.37 (+0.63), EXAS: 25.56 (-0.54)
Exact Sciences Names Michael S. Wygza to its Board of Directors
Business Wire - Wed Feb 11, 9:32AM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced the appointment of Michael S. Wygza to its board of directors. Wygza most recently served as President, Chief Executive Officer and a member of the board of directors of Radius Health, Inc.
RDUS: 50.37 (+0.63), EXAS: 25.56 (-0.54)
'Fast Money' Recap: How to Trade in a Gyrating Stock Market
at The Street - Sat Feb 07, 4:00AM CST
The trading panel discussed the strong dollar, oil prices and Tesla's earnings next week.
TSLA: 203.77 (+0.89), EEM: 40.67 (+0.46), EOG: 96.92 (+2.12), EXAS: 25.56 (-0.54), TWTR: 48.50 (+0.55), GDX: 21.26 (+0.11), TLT: 128.19 (-1.33), SCHW: 29.13 (-0.83)
Check-Cap on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 11:29AM CST
EXAS: 25.56 (-0.54)
Exact Sciences and Mayo Clinic Extend, Expand Collaboration to Continue Fighting Cancer through Advanced Screening
Business Wire - Fri Feb 06, 6:00AM CST
Exact Sciences Corp. (NASDAQ: EXAS) and Mayo Clinic today announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.
EXAS: 25.56 (-0.54)
Exact Sciences to Participate in Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will take part in the Leerink Global Healthcare Conference in New York.
EXAS: 25.56 (-0.54)
Exact Sciences Announces Norton Healthcare to Adopt Cologuard
Business Wire - Wed Jan 28, 2:30PM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard(R), the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure.
EXAS: 25.56 (-0.54)
Exact Sciences' Puzzling Early Launch Trajectory Update For Cologuard - An Analysis
SNJBiostoxx - at Seeking Alpha - Wed Jan 21, 5:30AM CST
EXAS: 25.56 (-0.54)
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 18, 8:12AM CST
Source: Flickr user Eric Norris Cancer of any type is a terrifying disease to fight. There are simply so many unknowns associated with cancer, such as why it occurs in one person and not the next and what triggers its growth in the first place. ...
MRK: 58.81 (-0.07), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
The Liquid Biopsy Will Boost Revenue For Sequenom And Illumina
Doug Van Cuyk - at Seeking Alpha - Thu Jan 15, 10:36AM CST
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81), EXAS: 25.56 (-0.54)
Why You Shouldn't Bet Against Exact Sciences (EXAS) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:40AM CST
Exact Sciences is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors
EXAS: 25.56 (-0.54)
Exact Sciences reports Cologuard volume for 2014
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:58AM CST
EXAS: 25.56 (-0.54)
Why Shares of Foundation Medicine, Inc. Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 10:52AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of Foundation Medicine rose by more than...
FMI: 48.88 (+0.17), AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
Exact Sciences Offers Update on Cologuard's(R) Early Launch Trajectory
Business Wire - Mon Jan 12, 8:04AM CST
Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, more than 4,000 physicians wrote at least one prescription for the test and that as of December 31, the patient compliance rate was 74.6 percent. The Company estimates revenue during the fourth quarter of 2014 from Cologuard was approximately $1.5 million. Exact Sciences has not completed preparation of its financial statements for 2014 and this revenue estimate is based on preliminary data.
EXAS: 25.56 (-0.54)
In Case You Missed it, This New Cancer Study is Terrifying
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is possibly the scariest diagnosis a patient can be given. Within the United States cancer is the second-leading cause of death behind only heart disease. It was responsible for nearly 577,000 deaths in...
MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), EXAS: 25.56 (-0.54)
Exact Sciences Rises 1.99% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Jan 09, 4:44PM CST
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $28.27 to a high of $29.20. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $28.70 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 25.56 (-0.54)
Exact Sciences Shares Up 14.6% Since SmarTrend's Buy Recommendation (EXAS)
Comtex SmarTrend(R) - Fri Jan 09, 9:35AM CST
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on October 10th, 2014 at $25.17. In approximately 3 months, Exact Sciences has returned 14.62% as of today's recent price of $28.85.
EXAS: 25.56 (-0.54)
